Technologies
PDF


WARF: P120330US02

New Treatment for Restenosis


INVENTORS -

K. Craig Kent, Shakti Goel, Lianwang Guo

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method to treat blood vessel restenosis by applying a combination of insulin and connective tissue growth factor.
OVERVIEWAtherosclerosis (hardening of the arteries) is the leading cause of death in the United States. It can be addressed by several procedures, including angioplasty and bypass. However, when a blood vessel is injured during surgery, restenosis (narrowing of the vessel) can occur within a few months. Of the two million patients who undergo this surgery every year, restenosis occurs in up to 50 percent of cases.

Currently, restenosis is treated by a drug called rapamycin delivered through stents. Unfortunately, stents may cause more damage and prevent healing, leading to thrombosis. These drawbacks have driven the search for alternative anti-restenosis treatments.
THE INVENTIONUW–Madison researchers have developed an anti-restenosis formula made of insulin and connective tissue growth factor (CTGF). CTGF is a large protein known to help grow and remodel smooth vessel muscle after damage. The combination of CTGF and insulin increases levels of elastic collagen (type III) to promote healthy healing. The composition can be applied as an external wrap at the site of surgery.
BUSINESS OPPORTUNITY
  • More than 700,000 coronary artery bypass grafts are performed in the United States every year.
APPLICATIONS
  • Preventing or reducing restenosis
  • Surgeries that could benefit from the new treatment include coronary artery bypass, endarterectomy, vein grafting and organ transplantation.
KEY BENEFITS
  • Promotes adaptive remodeling of blood vessels
  • Suppresses constriction and neointimal growth
  • Boosts levels of collagen III (elastic) relative to collagen I (rigid)
  • Easily applied as a perivascular wrap or patch
STAGE OF DEVELOPMENTThe combination of CTGF and insulin resulted in a significant synergistic increase in elastic collagen in rat aortic cells. Also, treated rat vessels showed an enlarged lumen area, increased external elastic lamina and decreased neointimal growth.
Contact Information
For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.